Drug Profile
BMS 844421
Alternative Names: BMS-844421; BMS-PCSK9RxLatest Information Update: 27 Mar 2012
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Bristol-Myers Squibb
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 31 Dec 2011 BMS 844421 is no longer licensed to Bristol-Myers Squibb worldwide